1. 14.2% of Annualized Relapse Rate with peginterferon beta-1a SC 125mcg every 2 weeks superior to 18.9% of Annualized Relapse Rate with peginterferon beta-1a SC 125mcg every 4 weeks for at least 2 years.4.75% of participants discontinued treatment due to adverse event. 30.8% of participants experienced high ALT and 20.8% of participants experienced high AST. 60.6% of participants experienced hyperglycemia. 70.8% of participants have elevated plasma protein. This evidence concerns the gene GDI1 and Hyperglycemia.